LLP2A-Ale, a Novel PDC Drug, Attenuates Osteoarthritis Progression by Modulating Subchondral Bone Remodeling and Chondroprotective Pathways in Osteoarthritis Models
Osteoarthritis and Cartilage · 2026-04 · 34 · S61-S62
DOI: 10.1016/j.joca.2026.01.059 ↗Kurz gefasst
Fachartikel in der Zeitschrift Osteoarthritis and Cartilage, 2026-04. Verfasst von Yonglong Cai und 6 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Cai, Y., Xiang, X., Jiang, M., Chen, C., Chen, J., Lane, N., & Yao, W. (2026). LLP2A-Ale, a Novel PDC Drug, Attenuates Osteoarthritis Progression by Modulating Subchondral Bone Remodeling and Chondroprotective Pathways in Osteoarthritis Models. Osteoarthritis and Cartilage, 34, S61-S62. https://doi.org/10.1016/j.joca.2026.01.059
Vancouver
Cai Y, Xiang X, Jiang M, Chen C, Chen J, Lane N, et al. LLP2A-Ale, a Novel PDC Drug, Attenuates Osteoarthritis Progression by Modulating Subchondral Bone Remodeling and Chondroprotective Pathways in Osteoarthritis Models. Osteoarthritis and Cartilage. 2026;34:S61-S62. doi:10.1016/j.joca.2026.01.059
BibTeX
@article{Cai2026,
author = {Cai, Yonglong and Xiang, Xuexiang and Jiang, Min and Chen, Charles and Chen, Jiwei and Lane, Nancy and Yao, Wei},
title = {LLP2A-Ale, a Novel PDC Drug, Attenuates Osteoarthritis Progression by Modulating Subchondral Bone Remodeling and Chondroprotective Pathways in Osteoarthritis Models},
journal = {Osteoarthritis and Cartilage},
year = {2026},
volume = {34},
pages = {S61--S62},
doi = {10.1016/j.joca.2026.01.059}
}
EUVIMED